ArticleInflammopharmacology2025
Therapeutic effect of formononetin in 6-OHDA induced Parkinson disease in rats.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Formononetin alleviates ovarian fibrosis and inflammation via targeting SOCS3 and inhibiting TGF-Chinese herbal medicines · 2026Article
- Pulmonary microbiota-associated formononetin modulates microglial activation in asthma-related anxiety.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preclinical models of Parkinson's disease (PD) have been developed using intracerebroventricular (i.c.v.) injection of 6-hydroxydopamine (6-OHDA) to induce neurodegeneration and motor dysfunction. Formononetin, a phytoestrogen with known anti-aging and anti-apoptotic properties, was investigated for its potential neuroprotective effects against 6-OHDA-induced toxicity. In this study, the rats received a single i.c.v. injection of 6-OHDA and were then treated with formononetin at doses of 25, 50, and 100 mg/kg orally for 21 days. Motor coordination, grip strength, and gait were evaluated using the rotarod test, gait analysis, and pole test. Biochemical assessments measured oxidative stress markers [superoxide dismutase (SOD), catalase, and glutathione (GSH)], proinflammatory cytokines (TNFα, IL-6, and IL-1β), and brain monoamines [dopamine (DA) and acetylcholine (ACh)]. Immunohistochemistry was performed to assess α-synuclein and B-cell lymphoma 2 (BCl2) protein expression. The results showed that formononetin significantly improved motor coordination, gait, and grip strength. It also enhanced antioxidant defenses by increasing SOD, catalase, and GSH activities, while reducing neuroinflammation by lowering IL-1β, TNFα, and IL-6 levels. Furthermore, formononetin alleviated DA depletion and reduced ACh levels, indicating its protective effect on dopaminergic neurons. The immunohistochemical analysis revealed that formononetin decreased α-synuclein aggregation and upregulated BCl2 expression, highlighting its neuroprotective and antioxidative properties. In conclusion, formononetin, at doses of 25, 50, and 100 mg/kg, exhibited significant neuroprotective effects in the 6-OHDA-induced PD rat model. By improving motor function, reducing oxidative stress, and attenuating neuroinflammation, formononetin holds promise as a potential therapeutic agent for PD.
Indexed as
Identifiers
40089961What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.